{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:08:03Z","timestamp":1792595283062,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11604-023-01398-y","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T19:25:13Z","timestamp":1675884313000},"page":"777-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)"],"prefix":"10.1007","volume":"41","author":[{"given":"Yiting","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"issue":"11","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1136\/jcp.2008.055335","volume":"61","author":"C Agostinelli","year":"2008","unstructured":"Agostinelli C, Piccaluga PP, Went P, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 2008;61(11):1160\u20137. https:\/\/doi.org\/10.1136\/jcp.2008.055335.","journal-title":"J Clin Pathol"},{"issue":"25","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"issue":"Suppl 5","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315. https:\/\/doi.org\/10.1093\/annonc\/mdv201.","journal-title":"Ann Oncol"},{"issue":"17","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636\u201344. https:\/\/doi.org\/10.1182\/blood-2013-12-516245.","journal-title":"Blood"},{"issue":"2","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Guti\u00e9rrez-Garc\u00eda","year":"2011","unstructured":"Guti\u00e9rrez-Garc\u00eda G, Garc\u00eda-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdq359.","journal-title":"Ann Oncol"},{"issue":"1","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Aggressives). Ann Oncol. 1990;1(1):45\u201350. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a057673.","journal-title":"Ann Oncol"},{"issue":"6","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","volume":"8","author":"F Foss","year":"2011","unstructured":"Foss F. Hematology: relapsed and refractory PTCL\u2013into the therapeutic abyss. Nat Rev Clin Oncol. 2011;8(6):321\u20132. https:\/\/doi.org\/10.1038\/nrclinonc.2011.51.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394. https:\/\/doi.org\/10.1056\/NEJM199309303291402.","journal-title":"N Engl J Med"},{"issue":"6","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837\u201342. https:\/\/doi.org\/10.1182\/blood-2013-09-524108.","journal-title":"Blood"},{"issue":"7","key":"1398_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139. https:\/\/doi.org\/10.1182\/blood-2003-09-3080.","journal-title":"Blood"},{"key":"1398_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lrr.2016.06.003","volume":"6","author":"A Nakaya","year":"2016","unstructured":"Nakaya A, Fujita S, Satake A, et al. Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma. Leuk Res Rep. 2016;6:24\u20136. https:\/\/doi.org\/10.1016\/j.lrr.2016.06.003.","journal-title":"Leuk Res Rep"},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.critrevonc.2016.07.003","volume":"106","author":"HJ Adams","year":"2016","unstructured":"Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;106:55\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.003.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","volume":"28","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Sch\u00f6der H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896\u2013903. https:\/\/doi.org\/10.1200\/JCO.2009.26.5942.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","volume":"15","author":"YL Kasamon","year":"2009","unstructured":"Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Trans. 2009;15(2):242\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2008.11.026.","journal-title":"Biol Blood Marrow Trans"},{"issue":"3","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","volume":"109","author":"EJ Dann","year":"2007","unstructured":"Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109(3):905\u20139. https:\/\/doi.org\/10.1182\/blood-2006-04-019901.","journal-title":"Blood"},{"issue":"1","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdp271","volume":"21","author":"A Avigdor","year":"2010","unstructured":"Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET\/CT scan is an effective regimen for advanced high-risk Hodgkin\u2019s lymphoma. Ann Oncol. 2010;21(1):126\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdp271.","journal-title":"Ann Oncol"},{"issue":"27","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229. (published correction appears in J Clin Oncol 2016 Jul 20;34(21):2562).","journal-title":"J Clin Oncol"},{"issue":"1","key":"1398_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12880-021-00674-5","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang G, Zhao X, et al. The role of pre-treatment and mid-treatment 18F-FDG PET\/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). BMC Med Imaging. 2021;21(1):145. https:\/\/doi.org\/10.1186\/s12880-021-00674-5.","journal-title":"BMC Med Imaging"},{"issue":"4","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719\u201324. https:\/\/doi.org\/10.1093\/annonc\/mdw011.","journal-title":"Ann Oncol"},{"issue":"3","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020. Ann Oncol. 2021;32(3):404\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.019.","journal-title":"Ann Oncol"},{"issue":"1","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.229450.","journal-title":"J Nucl Med"},{"issue":"3","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49(3):932\u201342. https:\/\/doi.org\/10.1007\/s00259-021-05480-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1398_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/hon.3025","volume":"40","author":"R Durmo","year":"2022","unstructured":"Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study. Hematol Oncol. 2022;40(4):645\u201357. https:\/\/doi.org\/10.1002\/hon.3025.","journal-title":"Hematol Oncol"},{"key":"1398_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9746716","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang X, Qin H, et al. Prognostic values of baseline 18F-FDG PET\/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020. https:\/\/doi.org\/10.1155\/2020\/9746716.","journal-title":"Biomed Res Int"},{"issue":"1","key":"1398_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-020-00698-y","volume":"10","author":"C Jiang","year":"2020","unstructured":"Jiang C, Teng Y, Chen J, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). EJNMMI Res. 2020;10(1):110. https:\/\/doi.org\/10.1186\/s13550-020-00698-y.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1398_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181\u2013200. https:\/\/doi.org\/10.1007\/s00259-009-1297-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1398_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2214\/AJR.09.3665","volume":"195","author":"J Feeney","year":"2010","unstructured":"Feeney J, Horwitz S, G\u00f6nen M, Sch\u00f6der H. Characterization of T-cell lymphomas by FDG PET\/CT. AJR Am J Roentgenol. 2010;195(2):333\u201340. https:\/\/doi.org\/10.2214\/AJR.09.3665.","journal-title":"AJR Am J Roentgenol"},{"issue":"59","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"99587","DOI":"10.18632\/oncotarget.20447","volume":"8","author":"CC Chang","year":"2017","unstructured":"Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587\u2013600. https:\/\/doi.org\/10.18632\/oncotarget.20447.","journal-title":"Oncotarget"},{"issue":"4","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.4143\/crt.2018.649","volume":"51","author":"JH Liang","year":"2019","unstructured":"Liang JH, Zhang YP, Xia J, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019;51(4):1479\u201387. https:\/\/doi.org\/10.4143\/crt.2018.649.","journal-title":"Cancer Res Treat"},{"issue":"4","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000321544","volume":"124","author":"S Yi","year":"2010","unstructured":"Yi S, An G, Qi J, et al. The significance of bone marrow involvement in aggressive lymphomas: a retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China. Acta Haematol. 2010;124(4):239\u201344. https:\/\/doi.org\/10.1159\/000321544.","journal-title":"Acta Haematol"},{"issue":"1","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/RLU.0000000000002320","volume":"44","author":"Y Koh","year":"2019","unstructured":"Koh Y, Lee JM, Woo GU, et al. FDG PET for evaluation of bone marrow status in T-cell lymphoma. Clin Nucl Med. 2019;44(1):4\u201310. https:\/\/doi.org\/10.1097\/RLU.0000000000002320.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1097\/RLU.0000000000002516","volume":"44","author":"Y Abe","year":"2019","unstructured":"Abe Y, Kitadate A, Usui Y, et al. Diagnostic and prognostic value of using 18F-FDG PET\/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma. Clin Nucl Med. 2019;44(5):e336\u201341. https:\/\/doi.org\/10.1097\/RLU.0000000000002516.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"1398_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/MNM.0000000000000579","volume":"37","author":"JP Hwang","year":"2016","unstructured":"Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET\/CT in patients with primary gastric lymphoma. Nucl Med Commun. 2016;37(12):1267\u201372. https:\/\/doi.org\/10.1097\/MNM.0000000000000579.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjoto.2017.10.009","volume":"39","author":"K Pak","year":"2018","unstructured":"Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET\/CT in patients with extranodal nasal type NK\/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1\u20135. https:\/\/doi.org\/10.1016\/j.amjoto.2017.10.009.","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"1398_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/hon.905","volume":"28","author":"JH Yi","year":"2010","unstructured":"Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28(2):57\u201361. https:\/\/doi.org\/10.1002\/hon.905.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1398_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.27855","volume":"119","author":"TM Kim","year":"2013","unstructured":"Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195\u2013202. https:\/\/doi.org\/10.1002\/cncr.27855.","journal-title":"Cancer"},{"key":"1398_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8659826","author":"J Yang","year":"2018","unstructured":"Yang J, Zhu S, Pang F, et al. Functional parameters of 18F-FDG PET\/CT in patients with primary testicular diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2018. https:\/\/doi.org\/10.1155\/2018\/8659826.","journal-title":"Contrast Media Mol Imaging"},{"issue":"4","key":"1398_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3109\/10428194.2013.831848","volume":"55","author":"N Nols","year":"2014","unstructured":"Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(4):773\u201380. https:\/\/doi.org\/10.3109\/10428194.2013.831848.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1398_CR40","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(9):1735\u201343. https:\/\/doi.org\/10.1007\/s00259-014-2783-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1398_CR41","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319. https:\/\/doi.org\/10.1007\/s00259-016-3315-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"1398_CR42","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large b-cell lymphoma. Clin Cancer Res. 2016;22(15):3801\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2825.","journal-title":"Clin Cancer Res"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01398-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-023-01398-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01398-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:32:34Z","timestamp":1688121154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-023-01398-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s11604-023-01398-y","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical standards set out in the 1964 Declaration of Helsinki and all subsequent revisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Approval was obtained from the institution review boards, and all of the subjects signed a written consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}